Impact of drug adherence on blood pressure response to alcohol-mediated renal denervation.


Journal

Blood pressure
ISSN: 1651-1999
Titre abrégé: Blood Press
Pays: England
ID NLM: 9301454

Informations de publication

Date de publication:
12 2022
Historique:
entrez: 16 5 2022
pubmed: 17 5 2022
medline: 20 5 2022
Statut: ppublish

Résumé

While poor drug adherence is frequent in patients with resistant hypertension, detailed analyses of the impact of drug adherence on the success of renal denervation are scarce. We report drug adherence at baseline, changes in drug adherence, and the influence of these parameters on blood pressure changes at 6 and 12 months in patients treated with alcohol-mediated renal denervation as part of the Peregrine study. Urinary detection of antihypertensive drugs was performed using high-performance liquid chromatography-tandem mass spectrometry. Full adherence, partial adherence, and complete non-adherence were defined as 0, 1, or ≥2 drugs not detected, respectively. Renal denervation was performed in 45 patients with uncontrolled hypertension on ≥3 antihypertensive medications (62% men, age 55 ± 10 years). At baseline, the proportion of fully, partially, and non-adherent patients was 62% ( About 40% of patients with apparently treatment-resistant hypertension were not fully adherent at baseline, and adherence decreased further in 30%. Nevertheless, mean blood pressure changes after renal denervation were similar irrespective of drug adherence. Our results suggest that such patients may benefit from alcohol-mediated renal denervation, irrespective of drug adherence. These findings are hypothesis-generating and need to be confirmed in ongoing sham-controlled trials.

Identifiants

pubmed: 35575248
doi: 10.1080/08037051.2022.2074367
doi:

Substances chimiques

Antihypertensive Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109-117

Auteurs

Alexandre Persu (A)

Division of Cardiology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.

Frédéric Maes (F)

Division of Cardiology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.

Stefan W Toennes (SW)

Institute of Legal Medicine, Goethe University, Frankfurt, Germany.

Sabrina Ritscher (S)

Institute of Legal Medicine, Goethe University, Frankfurt, Germany.

Coralie Georges (C)

Division of Cardiology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.

Pierre Wallemacq (P)

Clinical Chemistry Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.

Nicole Haratani (N)

Ablative Solutions, Inc., San Jose, CA, USA.

Helen Parise (H)

Ablative Solutions, Inc., San Jose, CA, USA.

Tim A Fischell (TA)

Ablative Solutions, Inc., San Jose, CA, USA.

Lucas Lauder (L)

Department of Internal Medicine III, Saarland University Medical Center, Homburg, Germany.

Felix Mahfoud (F)

Department of Internal Medicine III, Saarland University Medical Center, Homburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH